Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Phase III results of PROSPECT study for metastatic, castration-resistant prostate cancer

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 04.06.18
Views: 406

Dr James Gulley - Center for Cancer Research, Washington, USA

Dr Gulley speaks with ecancer at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting about the results of the PROSPECT study.

This is a randomised phase III trial of PROSTVAC-V/F in men with asymptomatic or minimally symptomatic metastatic, castration-resistant prostate cancer. PROSTVAC-V/F is a PSA-targeted, poxvirus-based cancer vaccine using a heterologous prime-boost regimen comprising a recombinant vaccinia vector prime followed by 6 booster doses with the recombinant fowlpox vector.

PROSPECT failed to confirm an overall survival benefit observed in a prior phase II study. He highlights the potential to combine with other checkpoint inhibitors in future trials, based on immune infiltrate data.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.
 

Related videos

follow us

NCRI 2018


Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation